RayzeBio
RayzeBio develops radiopharmaceutical cancer therapies and was acquired by Bristol Myers Squibb. The company has raised $418M and employs 281 people.
The growth story
RayzeBio grew from 51 to 281 employees between 2021 and 2026, raising $418M along the way, most recently a Series D in September 2022.
About
RayzeBio focuses on advancing radiopharmaceutical therapies for cancer treatment. These therapies use radioactive substances to target and destroy cancer cells, offering a potentially transformative approach to oncology.
The company has raised $418M, including a Series D round in September 2022. With 281 employees, RayzeBio operates in the competitive biotechnology research sector, leveraging its expertise to bring innovative treatments to patients.
Founders and leadership
RayzeBio's largest function is Research, with 51 employees dedicated to advancing its radiopharmaceutical therapies. The company is led by a team with deep experience in the biotechnology and pharmaceutical industries.
The RayzeBio org chart
Aron Knickerbocker (Co-Founder) leads 60 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 94 (+22% YoY), Operations 29 (+4% YoY), Healthcare Services 25 (+92% YoY), Quality Assurance 22 (+10% YoY), Program and Project Management 17 (+31% YoY), Information Technology 14 (+17% YoY).
Talent flow
RayzeBio's workforce includes many former employees of major pharmaceutical companies, with Bristol Myers Squibb, Eli Lilly, and Pfizer being the top sources. Alumni often move to other biotech firms, with AdvanCell and Crescent Biopharma being common destinations.
Most common previous employers of RayzeBio staff: Bristol Myers Squibb (30), Eli Lilly and Company (15), Pfizer (14), Mirati Therapeutics (10), Gilead Sciences (8), Thermo Fisher Scientific (8). Former RayzeBio employees most often moved to AdvanCell (3), Crescent Biopharma (3), Candid Therapeutics | Part of UCB S.A. (3), Z-Alpha Therapeutics (3), Neurocrine Biosciences (2), Eli Lilly and Company (2).
Alumni worth knowing
The RayzeBio mafia
RayzeBio alumni have founded several companies, including Decoy Therapeutics, Expedition Therapeutics, and ElevAAte Biotech, contributing to the broader biotech ecosystem.
6Jodi Cooper, was Senior Scientist II until 2022Yi Larson, was Board Member, Chair of Audit Committee until 2024Angie You, was Board Member until 2024Gang C., was Director, Discovery Radiochemstry until 2023Victor Rieber, was Associate Director, Digital Plants and Projects until 2025Deborah Charych, Ph.D., was Scientific Founder, Chief Technology/Science Officer, Advisor until 2022Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at RayzeBio: Microsoft Office (100), Leadership (78), Data Analysis (73), Project Management (72), Research Skills (71), Pharmaceutics (70), Communication (64), Microsoft Excel (64).
Where the team actually sits
RayzeBio people are concentrated in California, United States (81), Indiana, United States (56), United States (18), Greater Indianapolis (14).
Search footprint
RayzeBio attracts about 309 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 74 ranking keywords and lost 38 in the last period.
What employees say
- Compensation
- 4.50 / 5
- Career opportunities
- 3.50 / 5
- Senior management
- 3.50 / 5
- Work-life balance
- 4.20 / 5
Frequently asked
RayzeBio has 281 employees as of September 2026.
RayzeBio has raised $418M in total, most recently a Series D round in September 2022.
RayzeBio was founded in 2020 by Aron Knickerbocker.
Aron Knickerbocker (Co-Founder) sits at the top of RayzeBio's reporting structure, with 4 direct reports.
The most common previous employers of current RayzeBio staff are Bristol Myers Squibb (30 people), Eli Lilly and Company (15 people), Pfizer (14 people).
Former RayzeBio employees most often move to AdvanCell (3), Crescent Biopharma (3), Candid Therapeutics | Part of UCB S.A. (3).
At least 6 companies have a founder who previously worked at RayzeBio, including Decoy Therapeutics, Expedition Therapeutics, ElevAAte Biotech.
RayzeBio attracts about 309 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among RayzeBio staff are Microsoft Office, Leadership, Data Analysis, Project Management, Research Skills.
RayzeBio staff are concentrated in California, United States (81), Indiana, United States (56), United States (18).
RayzeBio has about 94 people in Research, up 22% over the past year, as of September 2026.
RayzeBio has about 29 people in Operations, up 4% over the past year, as of September 2026.
Computed from 234 current and 89 former RayzeBio profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.